WO2010123792A1 - Preparation of c-pyrazine-methylamines - Google Patents
Preparation of c-pyrazine-methylamines Download PDFInfo
- Publication number
- WO2010123792A1 WO2010123792A1 PCT/US2010/031547 US2010031547W WO2010123792A1 WO 2010123792 A1 WO2010123792 A1 WO 2010123792A1 US 2010031547 W US2010031547 W US 2010031547W WO 2010123792 A1 WO2010123792 A1 WO 2010123792A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- reaction
- carried out
- formula
- cioalkyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 C*N=C(c1ccccc1)c1ccccc1 Chemical compound C*N=C(c1ccccc1)c1ccccc1 0.000 description 2
- FTVLPTKJVLKKFJ-UHFFFAOYSA-N BrC(CC1)=CC2=C1CCC(c1ccccc1)=N2 Chemical compound BrC(CC1)=CC2=C1CCC(c1ccccc1)=N2 FTVLPTKJVLKKFJ-UHFFFAOYSA-N 0.000 description 1
- MLCNOCRGSBCAGH-UHFFFAOYSA-N Clc1nccnc1Cl Chemical compound Clc1nccnc1Cl MLCNOCRGSBCAGH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/16—Halogen atoms; Nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Definitions
- the present invention relates to a process for the preparation of C-pyrazine- methylamine compounds, and their conversion to l,3-substituted-imidazo[l,5- ⁇ ]pyrazines.
- US 2006/0235031 discloses the preparation of C-pyrazine-methylamine compounds, which is different from the process of preparation according to the present invention.
- the process described in the above-identified application while suitable for the synthesis of small quantities is not ideal for large scale manufacture.
- the stability of the intermediates from the process in the above-identified publication also needs to be improved. See also US 7232911.
- the present invention relates to a process for the preparation of C-pyrazine- methylamine compounds.
- the invention relates to a process for preparing C- pyrazin-2-ylmethylamine compounds of formula (I) or salts thereof:
- Rl is H or a substituent such as CN, a carboxylate, or an optionally substituted aryl or a heteroaryl group, by reaction of an appropriate arylimine with a dihalopyrazine, followed by hydrolysis.
- Another aspect of the invention relates to a process for preparing 1,3- substituted imidazo[l,5- ⁇ ]pyrazine compounds from a compound of formula I. DETAILED DESCRIPTION
- Rl is H, CN, a carboxylate, or optionally substituted aryl or heteroaryl; comprising reacting a 2,3-dihalopyrazine such as 2,3-dichloropyrazine with a suitable diaryl imine followed by hydrolysis.
- a 2,3-dihalopyrazine such as 2,3-dichloropyrazine
- Rl is aryl or heteroaryl, either of which is optionally substituted, such as by aryl, heteroaryl, Ci-Cioalkyl, Co-Cioalkoxy, halo, or cyano.
- the process provides compounds of formula I wherein Rl is aryl or heteroaryl;
- Step (a) the diaryl imine is prepared by Reaction A:
- Step (b) the diaryl imine product of (a) and the 2,3- dichloropyrazine are reacted together in the presence of base; and in some embodiments in Step (c) the product of (b) is hydrolyzed to obtain the compound of formula I.
- Reaction B is used to prepare the diaryl imine.
- Rl is an aryl group selected from phenyl, 4-chlorophenyl, A- fluorophenyl, 4-bromophenyl, 3-nitrophenyl, 2-methoxyphenyl, 2-methylphenyl, 3- methyphenyl, 4-methylphenyl, 4-ethylphenyl, 2-methyl-3-methoxyphenyl, 2,4-dibromophenyl, 3,5-difluorophenyl, 3,5-dimethylphenyl, 2,4,6-trichlorophenyl, 4-methoxyphenyl, naphthyl, 2- chloronaphthyl, 2,4-dimethoxyphenyl, 4-(trifluoromethyl)phenyl, or, 2-iodo-4-methylphenyl; and the aryl group is optionally substituted with one or more independent substituents selected from Ci-Cioalkyl, halo, cyano, hydroxy, or phenyl.
- Rl is a heteroaryl group selected from 2-, 3- or 4-pyridinyl, pyrazinyl, 2-, A-, or 5-pyrimidinyl, pyridazinyl, triazolyl, tetrazolyl, imidazolyl, 2- or 3-thienyl, 2- or 3-furyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, quinolyl, isoquinolyl, benzimidazolyl, benzotriazolyl, benzofuranyl, or benzothienyl; and the heteroaryl group is optionally substituted with one or more independent substituents selected from Ci-Cioalkyl, halo, cyano, hydroxy, or phenyl.
- Rl is 2-phenylquinoline.
- At least about 0.5 mol of formula I is obtained in an overall yield for the process of at least about 50%.
- the reaction solvent for (a) comprises THF or 1,4-dioxane.
- a diphenylmethylamine and an aryl aldehyde can be treated in a suitable solvent at a suitable reaction temperature.
- suitable solvents include ethers such as THF, glyme, and the like, CH3CN, chlorinated solvents such as
- reaction can be carried out at about atmospheric pressure although higher or lower pressures can be used. In some embodiments, approximately equimolar amounts of reactants can be used although higher or lower amounts can be used.
- Reaction A is carried out in the presence of an organic base and a Lewis acid.
- the organic base in Reaction A comprises Et 3 N or NMM.
- the Lewis acid comprises TiCl 4 .
- Suitable solvents include ethers such as THF, glyme, and the like, CH3CN; and chlorinated solvents such as CH 2 Cl 2 or CHCI3 and mixtures thereof.
- Preferred solvents include THF and 1,4-dioxane.
- the reaction can be carried out at about -78 ° C to about 120 0 C, preferably, about -78 ° C to about 20 0 C.
- the reaction can be carried out at about atmospheric pressure although higher or lower pressures can be used. In some embodiments, approximately equimolar amounts of reactants can be used although higher or lower amounts can be used.
- the reaction (b) of the diaryl imine with 2,3-dichloropyrazine is carried out in the presence of a metal hexamethyl disilazide, a metal amide, a metal hydride, a hindered alkoxide such as a tert-butoxide or tert-pentoxide, a metal carbonate or an organic base such as DBU.
- 2,3-dichloropyrazine and a (diphenylmethylidene)methanamine compound can be treated with a base in a suitable solvent at a suitable reaction temperature.
- suitable solvents for use in the reaction include ethers such as THF, glyme, 1,4-dioxane and the like, and mixtures thereof. Preferred solvents include THF.
- Suitable bases include HMDS sodium salt or potassium tert-butoxide.
- the reaction can be carried out at about -78 0 C to about 50 0 C, preferably about -20 0 C to about 25 0 C.
- the reaction can be carried out at about atmospheric pressure although higher or lower pressures can be used. In some embodiments, approximately equimolar amounts of reactants can be used although higher or lower amounts can be used.
- a l-(3-chloropyrazin-2-yl)-JV- (diphenylmethylidene)methanamine compound is treated with an acid, in a suitable solvent at a suitable reaction temperature.
- Suitable acids include HCl, sulfuric acid, or TFA.
- Suitable solvents for use in the reaction include ethers such as THF, glyme, and the like, esters such as EtOAc and the like, CH 3 CN, chlorinated solvents such as CH 2 Cl 2 or CHCl 3 , toluene, or HCl in MeOH. If desired, mixtures of these solvents can be used.
- Preferred solvents include CH 2 Cl 2 , EtOAc, THF and toluene.
- the reaction can be carried out at about -40 0 C to about 60 0 C, preferably, about 0 0 C to about 40 0 C.
- the reaction can be carried out at about atmospheric pressure although higher or lower pressures can be used. In some embodiments, approximately equimolar amounts of reactants can be used although higher or lower amounts can be used.
- Step (a) the diaryl imine is prepared by Reaction C: wherein R 2 is Ci-Cioalkyl; (b) the diaryl imine product of (a) and the 2,3- dichloropyrazine are reacted together in the presence of base; and (c) the product of (b) is hydrolyzed to obtain the compound of formula I wherein Rl is H.
- R 2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, te/t-butyl, n-pentyl, isopentyl, n-hexyl, n-heptyl, isooctyl, nonyl, decyl, any of which can be substituted by one or more independent substituents selected from Ci-Cioalkyl, halo, cyano, hydroxy, or phenyl.
- R 2 is methyl.
- At least about 0.5 mol of formula I is obtained in an overall yield for the process of at least about 50%.
- Reaction C is carried out in the presence of DIEA or Et 3 N.
- the base for (b) comprises potassium carbonate or cesium carbonate.
- (c) is carried out in the presence of potassium hydroxide, sodium hydroxide, or lithium hydroxide. In some embodiments, (c) is carried out in the presence of HCl, TFA, acetic acid, or sulfuric acid.
- an advantage of this process is that (3-chloropyrazin-2- yl)methanamine can be made without resorting to the formation of halomethyl pyrazine which is lacrymatory and difficult to form selectively.
- benzophenone can be reacted with a glycine alkyl ester in a suitable solvent at a suitable reaction temperature in the presence of a base.
- suitable solvents for use in the reaction included THF, glyme, and the like, propionitrile, acetonitrile, nonpolar solvents such as toluene, and chlorinated solvents such as CH 2 Cl 2 or CHCI3, or solvent mixtures.
- a preferred solvent is toluene.
- the reaction can be carried out at about -20
- glycine benzophenone imine compound can be reacted with 2,3-dichloropyrazine in a suitable solvent at a suitable temperature.
- Suitable solvents for use in the above process include THF, glyme, and the like, DMF, DMSO, propionitrile, Et 3 N, nonpolar solvents such as toluene, and chlorinated solvents such as CH2CI2 or CHCI3, or solvent mixtures.
- a preferred solvent is DMF.
- the reaction can be carried out at about -20 0 C to about 130 0 C, preferably, about 20 0 C to about 130 0 C. Bases such as potassium carbonate, cesium carbonate, DBU, or other bases can be used.
- the reaction can be carried out at about atmospheric pressure although higher or lower pressures can be used. In some embodiments, approximately equimolar amounts of reactants can be used although higher or lower amounts can be used.
- Suitable acids for use in the above process include HCl, TFA, acetic acid, and sulfuric acid.
- a preferred acid is HCl.
- Suitable bases include potassium hydroxide, sodium hydroxide, and lithium hydroxide.
- a preferred base is sodium hydroxide.
- Suitable solvents include water; nonpolar solvents such as toluene, alcohols, ethers such as THF, and chlorinated solvents such as CH 2 Cl 2 or CHCI3, or solvent mixtures.
- a preferred solvent is toluene.
- the reaction can be carried out at about -20 ° C to about 80 0 C, preferably, about 20 0 C to about 50 0 C.
- the reaction can be carried out at about atmospheric pressure although higher or lower pressures can be used. In some embodiments, approximately equimolar amounts of reactants can be used although higher or lower amounts can be used.
- the process further comprises reacting the compound of formula I according to the reactions:
- R 3 is Ci-Cioalkyl, C 3 -Ci 2 cycloalkyl, aryl, or heteroaryl, any of which is optionally substituted by one or more independent substituents selected from halo, oxo, cyano, hydroxy, and Ci-Cioalkyl; and R 4 is hydroxy, alkoxy, chloro, or imidazole.
- the process further comprises the reactions:
- a compound of formula (I) and a compound of Formula (III) are reacted under suitable amide coupling conditions.
- Suitable solvents include ethers such as tetrahydrofuran THF, glyme, and the like, DMF, DMSO, CH 3 CN, EtOAc, or halogenated solvents such as CHCl 3 or CH 2 Cl 2 , and solvent mixtures.
- Preferred solvents include CH 2 Cl 2 and DMF.
- the process can be carried out at about 0° C to about 80 0 C, preferably about room temperature (rt).
- the reaction can be carried out at about atmospheric pressure although higher or lower pressures can be used. In some embodiments, approximately equimolar amounts of reactants can be used although higher or lower amounts can be used.
- compounds of Formula (I) and (III) can be reacted with bases such as Et 3 N or DIEA or the like optionally in conjunction with DMAP or the like.
- Suitable solvents include ethers such as THF, glyme, and the like, DMF, CH 3 CN, EtOAc, halogenated solvents such as CH 2 Cl 2 or CHCl 3 , or mixtures thereof.
- a preferred solvent is CH 2 Cl 2 .
- the process can be carried out at about -20 0 C to about 40 0 C, preferably about 0 0 C to about 25 0 C.
- the reaction can be carried out at about atmospheric pressure although higher or lower pressures can be used.
- approximately equimolar amounts of reactants can be used although higher or lower amounts can be used.
- Other suitable reaction conditions for the conversion of a compound of Formula (I) to a compound of Formula (IV) can be found in Larock, R. C. Comprehensive Organic Transformations, 2 nd ed.; Wiley and Sons: New York, 1999, pp 1941-1949.
- an intermediate of Formula (IV) can be treated with POCI 3 , with or without a suitable solvent at a suitable reaction temperature.
- suitable solvents include ethers such as THF, glyme, DMF, EtOAc, and the like, CH3CN, and chlorinated solvents such as CH 2 Cl 2 or CHCI3, or mixtures of solvents.
- Preferred solvents include CH 3 CN, DMF, and CH 2 Cl 2 .
- the above process can be carried out at about 0 0 C. to about 120 0 C, preferably about 20 0 C to about 95 0 C.
- the reaction can be carried out at about atmospheric pressure although higher or lower pressures can be used. In some embodiments, approximately equimolar amounts of reactants can be used although higher or lower amounts can be used.
- Example 1 ⁇ /-[bis(4-methoxyphenyl)methylidene]-l-(2-phenylquinolin-7-yl)methanamine
- N- [bis(4-methoxyphenyl)methylidene] - 1 -(2-phenylquinolin-7-yl)methanamine (100 mg, 0.22 mmol) was added to a flask and protected by nitrogen.
- THF (2 rnL) was added and a clear solution was obtained.
- the solution was cooled to -5 0 C and then 1.0 M 1,1,1,3,3,3- hexamethyldisilazane, sodium salt in THF (0.26 mL, 0.26 mol) was added.
- 2,3- dichloropyrazine 36 mg, 0.24 mmol
- THF 1.0 mL
- Example 4 synthesis of (E)-l,l-diphenyl- ⁇ /-((2-phenylquinolin-7-yl)methylene)methanamine via a different starting material from that of Example 3
- 2-Phenylquinoline-7-carbaldehyde (85.00 g, 0.364 mol) and EtOAc (255 mL) were added to a rbf and heated in a 70 0 C oil bath.
- Half of aminodiphenylmethane 70.11 g, 0.38261 mol was added quickly. After 2 min, a light brown solid precipitated. The reaction was exothermic and the reaction temperature increased to 73 0 C. The remaining aminodiphenylmethane was then added within 3 min. The reaction temperature decreased to 67 0 C slowly. After 30 min, heating was discontinued and the reaction was cooled in an ice bath to about 15 0 C. The yellow solid was collected by vacuum filtration and dried in vacuo at 45 0 C overnight.
- Benzhydryl-[l-(2-phenyl-quinolin-7-yl)-meth-(E)-ylidene]-amine (12.50 g, 31.4 mmol) was added to a 500 mL rbf fitted with a thermocouple. The flask was degassed and filled with nitrogen. THF (150 mL) was added and the solid dissolved. The mixture was cooled to -5 0 C and 1.0 M of HMDS sodium salt in THF (39.2 mL) was added within 5 min. The temperature increased slightly to -3 0 C.
- the resultant aqueous solution was then transferred into a 250 mL round bottomed flask equipped with a magnetic stirrer and a nitrogen inlet.
- the solution was cooled to 5-10 0 C using an ice/water bath and sodium hydroxide (10 N, 7.8 mL, 76.9 mmol) was added and allowed to stir at rt for Ih. After the completion of the ester hydrolysis, the reaction mixture was cooled to 5-10 0 C.
- Example 7 In an alternative approach for hydrolysis, a 72 L round bottom flask equipped with mechanical stirrer, N 2 inlet/outlet and thermometer was charged with solution of crude pyrazine imine compound such as produced in Example 6 above ( ⁇ 30 L, 29.9 mol) in toluene. Water (12 L,) and concentrated HCl (3.2 L, 32.9 mol) was added and the reaction mixture was stirred at ambient temperature for 3 h (monitored by TLC). The layers were separated and aqueous layer was extracted with toluene (15 L).
- the aqueous solution was charged to the same reactor and concentrated HCl (3.2 L, 32.9 mol) was added. The reaction was heated at 60 0 C and monitored by TLC. After completion of the reaction (24-30 h) the reaction mixture was cooled to 5 to 10 0 C and the pH was adjusted to 10 with 50% aqueous NaOH (7 L) while maintaining the temperature below 10 0 C.
- 1H NMR (400 MHz or 300 MHz) spectra were recorded on Bruker or Varian instruments at ambient temperature with TMS or the residual solvent peak as the internal standard.
- the line positions or multiples are given in ppm ( ⁇ ) and the coupling constants (J) are given as absolute values in Hertz (Hz).
- the multiplicities in 1 H NMR spectra are abbreviated as follows: s (singlet), d (doublet), t (triplet), q (quartet), quint (quintet), m (multiplet), m c (centered multiplet), br or broad (broadened), AA'BB'. Flash chromatography was performed with silica gel (400-230 mesh).
- Mass-directed HPLC purification of compounds was performed on a Waters system composed of the following: 2767 Sample Manager, 2525 Binary Gradient Module, 600 Controller, 2487 Dual ⁇ Absorbance Detector, Micromass ZQ2000 for ionization, Phenomenex Luna 5 ⁇ C18(2) 100 A 150 x 21.2mm 5 ⁇ column with mobile phases of 0.01% formic acid acetonitrile (A) and 0.01% formic acid in HPLC water (B), a flow rate of 20 mL/min, and a run time of 13 min.
- LC-MS data was collected on ZQ2, ZQ3, or UPLC-ACQUITY.
- ZQ2 is an Agilent 1100 HPLC equipped with a Gilson 215 Liquid Handler, Gilson 819 Injection Module, and Waters Micromass ZQ2000 for ionization.
- ZQ3 is an Agilent 1100 HPLC equipped with an HP Series 1100 auto injector and Waters Micromass ZQ2000 for ionization. Both systems use the Xterra MS C18, 5 ⁇ particle size, 4.6 x 50 mm with a mobile phase of acetonitrile (A) and 0.01% formic acid in HPLC water (B). All Waters Micromass ZQ2000 instruments utilized electrospray ionization in positive (ES+) or negative (ES-) mode.
- ES+ positive
- ES- negative
- the Waters Micromass ZQ2000 instruments from ZQ2 and ZQ3 can also utilize atmospheric pressure chemical ionization in positive (AP+) or negative (AP-) mode.
- the Waters UPLC-ACQUITY system consists of an ACQUITY sample manager attached to ACQUITY SQ MS and ACQUITY PDA detectors. It uses an ACQUITY UPLC BEH ® C18 2.1x50mm 1.7 ⁇ m column with a mobile phase of 0.1 % formic acid in water (A) and 0.1% formic acid in acetonitrile (B). UV detection is at 254 nm, and the MS utilizes electrospray ionization in positive mode (ES+). All melting points were determined with a Mel-Temp II apparatus and are uncorrected. Elemental analyses were obtained by Atlantic Microlab, Inc., Norcross, GA.
- aryl refers to an all-carbon monocyclic, bicyclic, or poly cyclic groups of 6 to 12 carbon atoms having a completely conjugated pi-electron system.
- aryl include, but are not limited to, phenyl, 4-chlorophenyl, 4-fluorophenyl, A- bromophenyl, 3-nitrophenyl, 2-methoxyphenyl, 2-methylphenyl, 3-methyphenyl, A- methylphenyl, 4-ethylphenyl, 2-methyl-3-methoxyphenyl, 2,4-dibromophenyl, 3,5- difluorophenyl, 3,5-dimethylphenyl, 2,4,6-trichlorophenyl, 4-methoxyphenyl, naphthyl, 2- chloronaphthyl, 2,4-dimethoxyphenyl, 4-(trifluoromethyl)phenyl, and 2-iodo-4-methylphenyl.
- heteroaryl refer to a monocyclic, bicyclic, or polycyclic group of 5 to 12 ring atoms containing one or more ring heteroatoms selected from N, O, and S, the remaining ring atoms being C, and, in addition, having a completely conjugated pi-electron system.
- heteroaryl rings examples include, but are not limited to, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl.
- heteroaryl also include heteroaryl rings with fused carbocyclic ring systems that are partially or fully unsaturated, such as a benzene ring, to form a benzofused heteroaryl.
- heteroaryl include fused 5-6, 5-5, 6-6 ring systems, optionally possessing one nitrogen atom at a ring junction.
- examples of such hetaryl rings include, but are not limited to, pyrrolopyrimidinyl, imidazo[l,2- ⁇ ]pyridinyl, imidazo[2,l- ⁇ jthiazolyl, imidazo[4,5- ⁇ ]pyridine, pyrrolo[2,l : /][l,2,4]triazinyl, and the like.
- Heteroaryl groups may be attached to other groups through their carbon atoms or the heteroatom(s), if applicable. For example, pyrrole may be connected at the nitrogen atom or at any of the carbon atoms.
- alkyl means both branched and straight chain alkyl groups. Typical alkyl groups are methyl, ethyl, /? -propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-bvXy ⁇ , n-pentyl, isopentyl, n-hexyl, n-heptyl, isooctyl, nonyl, decyl, and the like.
- alkoxy includes both branched and straight chain terminal alkyl groups attached to a bridging oxygen atom. Typical alkoxy groups include methoxy, ethoxy, n- propoxy, isopropoxy, tert-bv ⁇ oxy and the like.
- halo refers to fluoro, chloro, bromo, or iodo.
- cycloalkyl refers to a carbon mono-cyclic, bicyclic, or polycyclic aliphatic ring structure, optionally substituted with for example, alkyl, hydroxy, oxo, and halo, such as cyclopropyl, methylcyclopropyl, cyclobutyl, cyclopentyl, 2- hydroxycyclopentyl, cyclohexyl, 4-chlorocyclohexyl, cycloheptyl, cyclooctyl, and the like.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
Claims
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012507282A JP2012524119A (en) | 2009-04-20 | 2010-04-19 | Preparation of C-pyrazine-methylamine |
| MX2011011025A MX2011011025A (en) | 2009-04-20 | 2010-04-19 | Preparation of c-pyrazine-methylamines. |
| EP10714546A EP2421837A1 (en) | 2009-04-20 | 2010-04-19 | Preparation of c-pyrazine-methylamines |
| US13/265,363 US8513415B2 (en) | 2009-04-20 | 2010-04-19 | Preparation of C-pyrazine-methylamines |
| CN2010800174272A CN102405214A (en) | 2009-04-20 | 2010-04-19 | Preparation of c-pyrazine-methylamines |
| BRPI1016245-3A BRPI1016245A2 (en) | 2009-04-20 | 2010-04-19 | Preparation of c-pyrazine methylamines. |
| CA2752826A CA2752826A1 (en) | 2009-04-20 | 2010-04-19 | Preparation of c-pyrazine-methylamines |
| US13/901,054 US20130261306A1 (en) | 2009-04-20 | 2013-05-23 | Preparation of c-pyrazine-methylamines |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17091109P | 2009-04-20 | 2009-04-20 | |
| US61/170,911 | 2009-04-20 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US13/901,054 Division US20130261306A1 (en) | 2009-04-20 | 2013-05-23 | Preparation of c-pyrazine-methylamines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2010123792A1 true WO2010123792A1 (en) | 2010-10-28 |
Family
ID=42269933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2010/031547 Ceased WO2010123792A1 (en) | 2009-04-20 | 2010-04-19 | Preparation of c-pyrazine-methylamines |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8513415B2 (en) |
| EP (1) | EP2421837A1 (en) |
| JP (1) | JP2012524119A (en) |
| KR (1) | KR20120020099A (en) |
| CN (1) | CN102405214A (en) |
| BR (1) | BRPI1016245A2 (en) |
| CA (1) | CA2752826A1 (en) |
| MX (1) | MX2011011025A (en) |
| WO (1) | WO2010123792A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014068104A1 (en) | 2012-11-05 | 2014-05-08 | Bayer Pharma Aktiengesellschaft | Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use as soluble guanylate cyclase stimulants |
| US9422285B2 (en) | 2013-08-08 | 2016-08-23 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolo[1,5-A]-pyridine-3-carboxamides and use thereof |
| US10174021B2 (en) | 2014-12-02 | 2019-01-08 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolo[1,5-A]pyridines and their use |
| US10214526B2 (en) | 2015-02-05 | 2019-02-26 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolo[1,5-a]-pyridine-3-carboxamides and use thereof |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20090495T1 (en) | 2004-04-02 | 2009-10-31 | Osi Pharmaceuticals | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
| CN103214424B (en) * | 2013-04-25 | 2015-05-13 | 兰州康寓信生物科技有限公司 | Synthesis method of pyrazine methylamine derivative |
| CN109553570A (en) * | 2017-09-27 | 2019-04-02 | 胜兴化工(上海)有限公司 | The preparation method of the chloro- 5- trifluoromethyl -2- pyridyl-methanamine salt of 3- |
| CN109182286B (en) * | 2018-09-21 | 2021-07-30 | 泰州学院 | An improved cyano reductase and its application in the synthesis of 3-chloropyrazine-2 methylamine |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1422220A1 (en) * | 2002-11-20 | 2004-05-26 | Bayer CropScience SA | Process for the preparation of 2-aminomethylpyridine derivative |
| US20060235031A1 (en) * | 2004-04-02 | 2006-10-19 | Arnold Lee D | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE791025A (en) | 1971-11-19 | 1973-05-07 | Allen & Hanburys Ltd | HETEROCYCLIC COMPOUNDS |
| US5217999A (en) | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
| WO1991015495A1 (en) | 1990-04-02 | 1991-10-17 | Pfizer Inc. | Benzylphosphonic acid tyrosine kinase inhibitors |
| US5302606A (en) | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
| US6645969B1 (en) | 1991-05-10 | 2003-11-11 | Aventis Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
| CA2108889A1 (en) | 1991-05-29 | 1992-11-30 | Robert Lee Dow | Tricyclic polyhydroxylic tyrosine kinase inhibitors |
| JP2914407B2 (en) | 1991-09-11 | 1999-06-28 | 富士電機株式会社 | vending machine |
| JP3240201B2 (en) * | 1992-04-28 | 2001-12-17 | 広栄化学工業株式会社 | Method for producing chloropyrazines |
| MX9304801A (en) | 1992-08-06 | 1997-06-28 | Warner Lambert Co | 2-thioindoles and related disulfides which inhibit protein tyrosine kinases and which have antitumor properties. |
| GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
| US20030108545A1 (en) | 1994-02-10 | 2003-06-12 | Patricia Rockwell | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| CH690773A5 (en) | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo (2,3-d) pyrimides and their use. |
| JP2000506880A (en) | 1996-03-15 | 2000-06-06 | ゼネカ・リミテッド | Cinnoline derivatives and uses thereof |
| US6232299B1 (en) | 1996-05-01 | 2001-05-15 | Eli Lilly And Company | Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy |
| GB9707800D0 (en) | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
| ZA200007412B (en) | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
| US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
| US6337338B1 (en) | 1998-12-15 | 2002-01-08 | Telik, Inc. | Heteroaryl-aryl ureas as IGF-1 receptor antagonists |
| EP2042194A3 (en) | 1999-05-14 | 2009-04-22 | Imclone Systems, Inc. | Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
| US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| DK1202746T3 (en) | 1999-08-12 | 2007-01-02 | Wyeth Corp | NSAID and EGFR kinase inhibitor-containing preparation for the treatment or inhibition of colon polyps and colorectal cancer |
| GB9919558D0 (en) | 1999-08-18 | 1999-10-20 | Hoechst Schering Agrevo Gmbh | Fungicidal compounds |
| US7087613B2 (en) | 1999-11-11 | 2006-08-08 | Osi Pharmaceuticals, Inc. | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
| AU2000240570A1 (en) | 2000-03-29 | 2001-10-08 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
| GB0008368D0 (en) | 2000-04-06 | 2000-05-24 | Astrazeneca Ab | Combination product |
| GB0017635D0 (en) | 2000-07-18 | 2000-09-06 | Pharmacia & Upjohn Spa | Antitumor combined therapy |
| WO2002045653A2 (en) | 2000-12-08 | 2002-06-13 | Uab Research Foundation | Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody |
| KR20030068205A (en) | 2001-01-09 | 2003-08-19 | 메르크 파텐트 게엠베하 | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors |
| EP1363702A4 (en) | 2001-01-30 | 2007-08-22 | Cytopia Pty Ltd | Methods of inhibiting kinases |
| MXPA03008560A (en) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Single-stage pfc + ballast control circuit/general purpose power converter. |
| KR20030083016A (en) | 2001-03-28 | 2003-10-23 | 브리스톨-마이어스스퀴브컴파니 | Novel Tyrosine Kinase Inhibitors |
| AU2002315306B2 (en) | 2001-05-08 | 2007-05-17 | Merck Patent Gmbh | Combination therapy using anti-EGFR antibodies and anti-hormonal agents |
| TWI238824B (en) | 2001-05-14 | 2005-09-01 | Novartis Ag | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives |
| SE0102168D0 (en) | 2001-06-19 | 2001-06-19 | Karolinska Innovations Ab | New use and new compounds |
| EP1463742A4 (en) | 2001-06-21 | 2006-05-10 | Ariad Pharma Inc | Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof |
| US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
| US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
| GB0122560D0 (en) | 2001-09-19 | 2001-11-07 | Aventis Pharma Ltd | Chemical compounds |
| AU2002337142B2 (en) | 2001-09-19 | 2007-10-11 | Aventis Pharma S.A. | Indolizines as kinase protein inhibitors |
| SE0104140D0 (en) | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
| CA2470088A1 (en) | 2001-12-20 | 2003-07-03 | Tularik Inc. | Identification of an amplified gene and target for drug intervention |
| US20050215564A1 (en) | 2002-02-14 | 2005-09-29 | Stiles Charles D | Methods and compositions for treating hyperproliferative conditions |
| US20030199525A1 (en) | 2002-03-21 | 2003-10-23 | Hirst Gavin C. | Kinase inhibitors |
| BR0309226A (en) | 2002-04-16 | 2005-02-09 | Astrazeneca Ab | Methods for producing a vascular damaging effect in a warm-blooded animal, and for treating cancer involving a solid tumor in a warm-blooded animal, pharmaceutical composition, kit, and uses of zd6126 or salt thereof pharmaceutically acceptable salt and zd1839 or a pharmaceutically acceptable salt thereof |
| DE10230605A1 (en) | 2002-07-08 | 2004-01-29 | Bayer Ag | Substituted imidazotriazines |
| DE10230604A1 (en) | 2002-07-08 | 2004-01-29 | Bayer Ag | Heterocyclically substituted imidazotriazines |
| MXPA05001688A (en) | 2002-08-12 | 2005-04-19 | Sugen Inc | 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors. |
| TW200501960A (en) | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
| US20040209930A1 (en) | 2002-10-02 | 2004-10-21 | Carboni Joan M. | Synergistic methods and compositions for treating cancer |
| DE10254853A1 (en) | 2002-11-25 | 2004-06-03 | Basf Ag | Improved process for the production of cyclopentenones |
| UA80171C2 (en) | 2002-12-19 | 2007-08-27 | Pfizer Prod Inc | Pyrrolopyrimidine derivatives |
| US7186832B2 (en) | 2003-02-20 | 2007-03-06 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| US7157460B2 (en) | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| AP2005003390A0 (en) | 2003-03-12 | 2005-09-30 | Pfizer Prod Inc | Pyridyloxymethyl and benzisoxazole azabicyclic derivatives. |
| US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| ES2372694T3 (en) | 2003-10-15 | 2012-01-25 | OSI Pharmaceuticals, LLC | INHIBITORS OF TYPEOSIN KINASE IMIDAZO [1,5-A] PIRAZINA. |
| PE20050928A1 (en) | 2003-11-21 | 2005-11-08 | Schering Corp | THERAPEUTIC COMBINATIONS OF ANTI-IGFR1 ANTIBODY |
| WO2005061519A1 (en) | 2003-12-19 | 2005-07-07 | Takeda San Diego, Inc. | Kinase inhibitors |
| EP1747217A1 (en) * | 2004-05-13 | 2007-01-31 | Boehringer Ingelheim International GmbH | Novel substituted thiophenecarboxamides, their production and their use as medicaments |
| RU2006146612A (en) | 2004-06-03 | 2008-07-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | TREATMENT OF EPIDERMAL GROWTH FACTOR (EGFR) RECEPTOR AND CISPLATIN AND INHIBITOR |
| MXPA06015237A (en) | 2004-06-29 | 2007-12-10 | Amgen Inc | Pyrrolo[2,3-d]pyrimidines that modulate ack1 and lck activity. |
| AR053090A1 (en) | 2004-07-20 | 2007-04-25 | Osi Pharm Inc | IMIDAZOTRIAZINS AS PROTEIN KINASE INHIBITORS AND THEIR USE FOR THE PREPARATION OF MEDICINES |
| US7674907B2 (en) | 2004-07-23 | 2010-03-09 | Amgen Inc. | Furanopyridine derivatives and methods of use |
| US20070149567A1 (en) | 2004-09-23 | 2007-06-28 | Pfizer Inc | Quinoline compounds |
| WO2006033001A1 (en) | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Quinoline compounds |
| DE202005016343U1 (en) | 2005-10-19 | 2007-02-22 | Weidmüller Interface GmbH & Co. KG | Electrical plug connection with quick release |
| ES2436877T3 (en) | 2005-11-17 | 2014-01-07 | OSI Pharmaceuticals, LLC | Intermediates for the preparation of condensed bicyclic mTOR inhibitors |
| AR057960A1 (en) | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | BICYCLE PROTEIN QUINASE INHIBITORS |
| EP1981854B1 (en) * | 2005-12-14 | 2011-06-01 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors |
| US8575164B2 (en) | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
| US20080299113A1 (en) | 2005-12-19 | 2008-12-04 | Arnold Lee D | Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents |
| TW200801008A (en) * | 2005-12-29 | 2008-01-01 | Abbott Lab | Protein kinase inhibitors |
| US7659274B2 (en) | 2006-01-25 | 2010-02-09 | Osi Pharmaceuticals, Inc. | Unsaturated mTOR inhibitors |
| WO2007106503A2 (en) | 2006-03-13 | 2007-09-20 | Osi Pharmaceuticals, Inc. | Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors |
| DE602007006010D1 (en) | 2006-05-31 | 2010-06-02 | Galapagos Nv | TRIAZOLOPYRAZIN COMPOUNDS FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES |
| PL2526933T3 (en) | 2006-09-22 | 2015-08-31 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
| JP2008105970A (en) * | 2006-10-24 | 2008-05-08 | Ohara Yakuhin Kogyo Kk | Process for preparing dihydroquinoline derivative and its intermediate |
| TW200900070A (en) | 2007-02-27 | 2009-01-01 | Osi Pharm Inc | Combination cancer therapy |
| JP2010532756A (en) | 2007-07-06 | 2010-10-14 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | Combination anti-cancer therapy comprising inhibitors of both mTORC1 and mTORC2 |
| US20090263397A1 (en) | 2007-07-06 | 2009-10-22 | Buck Elizabeth A | Combination anti-cancer therapy |
| CA2694154A1 (en) | 2007-10-03 | 2009-04-09 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| JP2011510018A (en) | 2008-01-18 | 2011-03-31 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | Imidazopyrazinol derivatives for cancer treatment |
| EP2283020B8 (en) | 2008-05-19 | 2012-12-12 | OSI Pharmaceuticals, LLC | Substituted imidazopyr-and imidazotri-azines |
| CA2758297A1 (en) | 2009-04-16 | 2010-10-21 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
| JP2012526138A (en) | 2009-05-07 | 2012-10-25 | オーエスアイ・ファーマシューティカルズ,エルエルシー | Use of OSI-906 to treat adrenocortical cancer |
| WO2011112666A1 (en) | 2010-03-09 | 2011-09-15 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| PH12012502495A1 (en) | 2010-06-23 | 2013-02-11 | Osi Pharmaceuticals Llc | Polymorphs of osi-906 |
| WO2012129145A1 (en) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Nscle combination therapy |
-
2010
- 2010-04-19 CN CN2010800174272A patent/CN102405214A/en active Pending
- 2010-04-19 BR BRPI1016245-3A patent/BRPI1016245A2/en not_active IP Right Cessation
- 2010-04-19 EP EP10714546A patent/EP2421837A1/en not_active Withdrawn
- 2010-04-19 MX MX2011011025A patent/MX2011011025A/en not_active Application Discontinuation
- 2010-04-19 JP JP2012507282A patent/JP2012524119A/en active Pending
- 2010-04-19 KR KR1020117020844A patent/KR20120020099A/en not_active Withdrawn
- 2010-04-19 CA CA2752826A patent/CA2752826A1/en not_active Abandoned
- 2010-04-19 US US13/265,363 patent/US8513415B2/en not_active Expired - Fee Related
- 2010-04-19 WO PCT/US2010/031547 patent/WO2010123792A1/en not_active Ceased
-
2013
- 2013-05-23 US US13/901,054 patent/US20130261306A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1422220A1 (en) * | 2002-11-20 | 2004-05-26 | Bayer CropScience SA | Process for the preparation of 2-aminomethylpyridine derivative |
| US20060235031A1 (en) * | 2004-04-02 | 2006-10-19 | Arnold Lee D | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors |
Non-Patent Citations (2)
| Title |
|---|
| N. SOTOMAYOR, TETRAHEDRON, vol. 50, 1994, pages 2207 |
| See also references of EP2421837A1 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014068104A1 (en) | 2012-11-05 | 2014-05-08 | Bayer Pharma Aktiengesellschaft | Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use as soluble guanylate cyclase stimulants |
| US9422285B2 (en) | 2013-08-08 | 2016-08-23 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolo[1,5-A]-pyridine-3-carboxamides and use thereof |
| US10174021B2 (en) | 2014-12-02 | 2019-01-08 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolo[1,5-A]pyridines and their use |
| US10214526B2 (en) | 2015-02-05 | 2019-02-26 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolo[1,5-a]-pyridine-3-carboxamides and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120020099A (en) | 2012-03-07 |
| US20120041202A1 (en) | 2012-02-16 |
| JP2012524119A (en) | 2012-10-11 |
| MX2011011025A (en) | 2011-11-02 |
| US20130261306A1 (en) | 2013-10-03 |
| US8513415B2 (en) | 2013-08-20 |
| EP2421837A1 (en) | 2012-02-29 |
| CN102405214A (en) | 2012-04-04 |
| CA2752826A1 (en) | 2010-10-28 |
| BRPI1016245A2 (en) | 2015-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2421837A1 (en) | Preparation of c-pyrazine-methylamines | |
| US6136971A (en) | Preparation of sulfonamides | |
| CN107531677A (en) | Method for preparing topicastat and intermediates thereof | |
| CA2397258C (en) | Preparation of sulfonamides | |
| JP4579821B2 (en) | Process for producing pyrimidine compounds | |
| CN104603116A (en) | Method for producing oxazole compound | |
| WO2004083212A1 (en) | Process to beta-ketoamide intermediates to dipeptidyl peptidase inhibitors | |
| US20120108812A1 (en) | Process for substituted 3-amino-5-oxo-4,5-dihydro-[1,2,4]triazines | |
| CN102245591B (en) | Process for manufacturing 5-formyl-pyridine-2,3-dicarboxylic acid esters | |
| CN102083823B (en) | The preparation method of 1-Biphenylmethyl imidazole compound | |
| KR20200128707A (en) | Method for preparing soluble guanylate cyclase stimulant | |
| JP3101974B2 (en) | Process for producing 4,6-diamino-1,3,5-triazin-2-yl-benzoic acids | |
| EP2217585A2 (en) | Process for the preparation of 2h-chromene-3-carbamate derivatives | |
| WO2025240628A1 (en) | Processes for preparing a pkc inhibitor | |
| Rigo et al. | Studies on pyrrolidinones. a silylated approach to fused triazoles | |
| KR20250090216A (en) | Process for Preparing Relugolix | |
| KR100856133B1 (en) | Improved process for preparing atorvastatin | |
| Khalafallah et al. | Synthesis of several polyfunctionally substituted fused pyrimidines incorporating quinone compounds | |
| JP2000327622A (en) | Production of phenylacetic acid derivative | |
| CN1726195A (en) | The preparation method of pyrimidine compound | |
| HK40007530A (en) | Method for producing oxazole compound | |
| HK40032181A (en) | Process for preparing aminopyrimidine derivatives | |
| Bakavolia et al. | e-mail: mbakavoli@ yahoo. com | |
| EP1654239A2 (en) | Peptide deformylase inhibitors | |
| JP2001072680A (en) | New method for producing purine iodide derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 201080017427.2 Country of ref document: CN |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10714546 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2752826 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2010714546 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref document number: 20117020844 Country of ref document: KR Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 7510/CHENP/2011 Country of ref document: IN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2011/011025 Country of ref document: MX |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 13265363 Country of ref document: US Ref document number: 2012507282 Country of ref document: JP |
|
| REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI1016245 Country of ref document: BR |
|
| ENP | Entry into the national phase |
Ref document number: PI1016245 Country of ref document: BR Kind code of ref document: A2 Effective date: 20111019 |





















